HDAC inhibition sensitises triple-negative breast cancer cells to PARP inhibition

A need for clarity in clinical trial end points

Neratinib shows beneficial effects in the treatment of HER2 mutated breast cancer

Adjuvant chemotherapy for locally recurrent breast cancer

Breast cancer hypo-fractionated radiotherapy offers long-term tumour control

Effectiveness of sentinel lymph node surgery after chemotherapy in node-positive breast cancer

Extending adjuvant trastuzumab treatment time provided no additional benefit

Breast cancer genome sequencing identified HER2 mutations as targets for drug treatment

Cognitive problems may be present before chemotherapy in women with breast cancer

BEATRICE study, adjuvant bevacizumab did not improve invasive disease-free survival in triple-negative breast cancer

Phase III trial did not show superiority of eribulin compared with capecitabine in metastatic breast cancer

HDAC inhibitors sensitise triple-negative breast cancer cells to PARP inhibition and cisplatin treatment